These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27569835)

  • 21. Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly.
    Iwanuk N; Wall L; Nolte I; Raue J; Rumstedt K; Pilgram A; Sehn M; Rohn K; Bach JP
    PLoS One; 2019; 14(10):e0223164. PubMed ID: 31581204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left ventricular twist and circumferential strain in dogs with myxomatous mitral valve disease.
    Zois NE; Olsen NT; Moesgaard SG; Rasmussen CE; Falk T; Häggström J; Pedersen HD; Møller JE; Olsen LH
    J Vet Intern Med; 2013; 27(4):875-83. PubMed ID: 23731222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    Mizuno M; Yamano S; Chimura S; Hirakawa A; Takusagawa Y; Sawada T; Maetani S; Takahashi A; Mizuno T; Harada K; Shinoda A; Uchida S; Takeuchi J; Mizukoshi T; Endo M; Uechi M
    J Vet Med Sci; 2017 Jan; 79(1):29-34. PubMed ID: 27644192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic value of vertebral left atrial size as determined from thoracic radiographs for assessment of left atrial size in dogs with myxomatous mitral valve disease.
    Malcolm EL; Visser LC; Phillips KL; Johnson LR
    J Am Vet Med Assoc; 2018 Oct; 253(8):1038-1045. PubMed ID: 30272515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pimobendan for mitral valve regurgitation in dogs.
    Kanno N; Kuse H; Kawasaki M; Hara A; Kano R; Sasaki Y
    J Vet Med Sci; 2007 Apr; 69(4):373-7. PubMed ID: 17485924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. R-R interval variations influence the degree of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Reimann MJ; Møller JE; Häggström J; Markussen B; Holen AE; Falk T; Olsen LH
    Vet J; 2014 Mar; 199(3):348-54. PubMed ID: 24507881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves.
    Surachetpong S; Jiranantasak T; Rungsipipat A; Orton EC
    J Vet Cardiol; 2013 Sep; 15(3):171-80. PubMed ID: 23816827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Echocardiographic evaluation of regurgitant fraction in dogs with subclinical myxomatous mitral valve disease: Method comparison, effects of pimobendan, and reproducibility.
    Ellis-Reis RE; Visser LC; Hsue W; Sharpe AN; Kaplan JL
    J Vet Cardiol; 2023 Feb; 45():27-40. PubMed ID: 36630740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radial and longitudinal strain and strain rate assessed by speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
    Zois NE; Tidholm A; Nägga KM; Moesgaard SG; Rasmussen CE; Falk T; Häggström J; Pedersen HD; Åblad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(6):1309-19. PubMed ID: 23113772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.
    Tidholm A; Höglund K; Häggström J; Ljungvall I
    J Vet Intern Med; 2015; 29(6):1510-7. PubMed ID: 26365438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The longitudinal outcome of canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: Baseline treatment characteristics.
    Franchini A; Borgarelli M; Abbott JA; Menciotti G; Crosara S; Häggström J; Lahmers S; Rosenthal S; Tyrrell W
    J Vet Cardiol; 2022 Jun; 41():99-120. PubMed ID: 35316716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease.
    Hezzell MJ; Falk T; Olsen LH; Boswood A; Elliott J
    J Vet Cardiol; 2014 Dec; 16(4):257-64. PubMed ID: 25292459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease.
    Borgarelli M; Abbott J; Braz-Ruivo L; Chiavegato D; Crosara S; Lamb K; Ljungvall I; Poggi M; Santilli RA; Haggstrom J
    J Vet Intern Med; 2015; 29(2):569-74. PubMed ID: 25818210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
    Dickson D; Caivano D; Matos JN; Summerfield N; Rishniw M
    J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
    J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S; Green D; Christley R; Dukes-McEwan J
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mitral valve morphology assessed by three-dimensional transthoracic echocardiography in healthy dogs and dogs with myxomatous mitral valve disease.
    Menciotti G; Borgarelli M; Aherne M; Wesselowski S; Häggström J; Ljungvall I; Lahmers SM; Abbott JA
    J Vet Cardiol; 2017 Apr; 19(2):113-123. PubMed ID: 28279678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration.
    Pirintr P; Saengklub N; Limprasutr V; Sawangkoon S; Kijtawornrat A
    J Vet Med Sci; 2017 Sep; 79(9):1480-1488. PubMed ID: 28717064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Holter monitoring of small breed dogs with advanced myxomatous mitral valve disease with and without a history of syncope.
    Rasmussen CE; Falk T; Domanjko Petrič A; Schaldemose M; Zois NE; Moesgaard SG; Ablad B; Nilsen HY; Ljungvall I; Höglund K; Häggström J; Pedersen HD; Bland JM; Olsen LH
    J Vet Intern Med; 2014; 28(2):363-70. PubMed ID: 24417236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease.
    Ouellet M; Bélanger MC; Difruscia R; Beauchamp G
    J Vet Intern Med; 2009; 23(2):258-63. PubMed ID: 19143935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.